Calidi Biotherapeutics Inc
CLDI0.592USD
+0.001+0.25%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
0.581USD+0.581After-hours (ET)
18.82MMarket Cap
LossP/E TTM
Calidi Biotherapeutics Inc
0.592
+0.001+0.25%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Total revenue
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--45.00K
--405.00K
Revenue
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--45.00K
--405.00K
Cost of revenue
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--14.00K
--50.00K
Operating expenses
-25.03%5.06M
-59.00%4.03M
-27.63%5.23M
-11.70%5.77M
24.71%6.75M
109.47%9.82M
3.36%7.22M
49.18%6.54M
-23.93%5.41M
44.65%4.69M
--6.99M
--4.38M
--7.12M
--3.24M
R&D expenses
-11.59%2.42M
-54.14%1.81M
-33.77%2.15M
-31.79%2.17M
4.61%2.74M
74.90%3.96M
67.15%3.25M
114.08%3.18M
67.54%2.62M
81.62%2.26M
--1.94M
--1.48M
--1.56M
--1.25M
Depreciation, depletion, and amortization
-1.96%100.00K
-1.01%98.00K
17.24%102.00K
-11.50%100.00K
9.68%102.00K
1.02%99.00K
40.32%87.00K
135.42%113.00K
78.85%93.00K
104.17%98.00K
--62.00K
--48.00K
--52.00K
--48.00K
Operating profit
25.03%-5.06M
59.00%-4.03M
27.63%-5.23M
11.70%-5.77M
-24.71%-6.75M
-109.47%-9.82M
-3.36%-7.22M
-49.18%-6.54M
23.44%-5.41M
-65.30%-4.69M
---6.99M
---4.38M
---7.07M
---2.84M
Net non-operating interest income (expenses)
Non-operating interest expense
-71.54%72.00K
-21.17%175.00K
-28.40%232.00K
-10.78%273.00K
16.59%253.00K
126.53%222.00K
1017.24%324.00K
1600.00%306.00K
1569.23%217.00K
58.06%98.00K
--29.00K
--18.00K
--13.00K
--62.00K
Special income (expenses)
117.59%35.00K
-96.07%48.00K
-92.16%380.00K
102.47%95.00K
86.85%-199.00K
141.22%1.22M
192.52%4.85M
-2189.88%-3.85M
-131.35%-1.51M
-398.32%-2.96M
--1.66M
---168.00K
---654.00K
---594.00K
Other non-operating income (expenses)
335.29%40.00K
-98.64%8.00K
-98.83%8.00K
110.57%191.00K
-102.48%-17.00K
4638.46%590.00K
17025.00%685.00K
-60333.33%-1.81M
68500.00%686.00K
-316.67%-13.00K
--4.00K
--3.00K
--1.00K
--6.00K
Income before tax
29.94%-5.06M
49.65%-4.14M
-151.86%-5.07M
53.92%-5.76M
-11.81%-7.22M
-6.10%-8.23M
62.40%-2.01M
-173.76%-12.50M
16.54%-6.46M
-122.58%-7.76M
---5.35M
---4.56M
---7.74M
---3.49M
Income tax
-25.00%3.00K
200.00%3.00K
-109.09%-1.00K
100.00%8.00K
0.00%4.00K
0.00%-3.00K
1000.00%11.00K
-63.64%4.00K
100.00%4.00K
-200.00%-3.00K
--1.00K
--11.00K
--2.00K
--3.00K
Income after tax
29.94%-5.06M
49.59%-4.15M
-150.44%-5.07M
53.87%-5.77M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net income from continuous operations
29.94%-5.06M
49.59%-4.15M
-150.44%-5.07M
53.87%-5.77M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net Income attributable to non-controlling interests
---76.00K
---51.00K
---15.00K
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
30.99%-4.99M
50.21%-4.10M
-149.70%-5.05M
40.50%-7.44M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net income attributable to common shareholders
30.99%-4.99M
50.21%-4.10M
-149.70%-5.05M
40.50%-7.44M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Basic earnings per share
90.94%-0.18
82.57%-0.27
-45.06%-0.65
-407.57%-13.96
-42.94%-2.03
9.93%-1.54
62.21%-0.45
-173.18%-2.75
16.51%-1.42
-122.30%-1.71
---1.18
---1.01
---1.70
---0.77
Diluted earnings per share
90.94%-0.18
82.57%-0.27
-45.06%-0.65
-407.57%-13.96
-42.94%-2.03
9.93%-1.54
62.21%-0.45
-173.18%-2.75
16.51%-1.42
-122.30%-1.71
---1.18
---1.01
---1.70
---0.77
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
--
--
